Sugi Predict

Sugi Predict / Compounds / SCHEMBL5860477

SCHEMBL5860477

SCHEMBL5860477

O=C(OCc1ccccc1C(=O)O)c1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PPARG P37231 1/20 0.61
▸ TDP1 Q9NUW8 2/20 0.59
▸ SLC6A2 P23975 1/20 0.59
▸ SLC6A3 Q01959 1/20 0.59
▸ KMT2A Q03164 1/20 0.59
▸ L3MBTL1 Q9Y468 1/20 0.55
▸ ALDH1A1 P00352 2/20 0.54
▸ TP53 P04637 1/20 0.51
▸ HTT P42858 1/20 0.51
▸ LMNA P02545 3/20 0.50
▸ MAPK1 P28482 2/20 0.50
▸ HIF1A Q16665 1/20 0.50
▸ NPSR1 Q6W5P4 1/20 0.49
▸ TSHR P16473 2/20 0.49
▸ FOLH1 Q04609 2/20 0.49
▸ MRGPRX4 Q96LA9 1/20 0.47
▸ AKR1C3 P42330 1/20 0.46
▸ F2 P00734 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6639780 0.98 PPARG (0.59) PPARGTDP1SLC6A2SLC6A3KMT2A
SCHEMBL3290977 0.88 PPARG (0.59) PPARGTDP1SLC6A2SLC6A3KMT2A
SCHEMBL2069592 0.87 TDP1 (0.69) PPARGTDP1SLC6A2SLC6A3KMT2A
SCHEMBL5085480 0.87 PPARG (0.71) PPARGTDP1SLC6A2SLC6A3KMT2A
SCHEMBL11011533 0.86 PPARG (0.58) PPARGTDP1SLC6A2SLC6A3KMT2A
SCHEMBL3290980 0.86 PPARG (0.58) PPARGTDP1SLC6A2SLC6A3KMT2A
SCHEMBL3293498 0.86 PPARG (0.58) PPARGTDP1SLC6A2SLC6A3KMT2A
SCHEMBL14544525 0.86 PPARG (0.58) PPARGTDP1SLC6A2SLC6A3KMT2A
SCHEMBL27596938 0.86 TDP1 (0.61) PPARGTDP1SLC6A2SLC6A3KMT2A
SCHEMBL112131 0.86 PPARG (0.58) PPARGTDP1SLC6A2SLC6A3KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023150540-A1 HYDROXAMIC ACID MACROCYCLIC AGENTS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF LUMIPHORE, INC. (US) 2023-08-10 — — WO disclosed
US-7786328-B2 Cyclohexyl-1,4-diamine compounds GRUENENTHAL GMBH (DE) 2010-08-31 — — US disclosed
US-7786328-B2 Cyclohexyl-1,4-diamine compounds GRUENENTHAL GMBH (DE) 2010-08-31 — — US disclosed
US-20070281954-A1 Cyclohexyl-1,4-diamine compounds GRUENENTHAL GMBH (DE) 2007-12-06 — — US disclosed
US-20070281954-A1 Cyclohexyl-1,4-diamine compounds GRUENENTHAL GMBH (DE) 2007-12-06 — — US disclosed
US-6989384-B2 Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis AGOURON PHARMACEUTICALS, INC. (US) 2006-01-24 — — US disclosed
US-20050080121-A1 Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis AGOURON PHARMACEUTICALS, INC. 2005-04-14 — — US disclosed
EP-0986386-B1 USE OF NITROGEN HETEROCYCLIC AROMATIC DERIVATIVES IN THE TOPICAL TREATMENT OF THE EPITHELIAL TISSUES DISEASES CROSS PROJECT SA (CH) 2004-03-03 — — EP disclosed
EP-1355878-A2 ANTIPICORNAVIRAL COMPOUNDS AND COMPOSITIONS, THEIR PHARMACEUTICAL USES, AND MATERIALS FOR THEIR SYNTHESIS AGOURON PHARMACEUTICALS, INC. (US) 2003-10-29 — — EP disclosed
US-6632825-B2 Picornaviral 3C protease enzyme inhibitors; amide ester or amide acid derivatives AGOURON PHARMACEUTICALS, INC. 2003-10-14 — — US disclosed
WO-2000001692-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2000-01-13 — — WO disclosed
WO-1998055118-A2 USE OF NITROGEN HETEROCYCLIC AROMATIC DERIVATIVES IN THE TOPICAL TREATMENT OF THE EPITHELIAL TISSUES DISEASES GEANGE LTD. (IE) 1998-12-10 — — WO disclosed
EP-0863875-A1 NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY F. HOFFMANN-LA ROCHE AG (CH) 1998-09-16 — — EP disclosed
WO-1997009311-A1 NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY F. HOFFMANN-LA ROCHE AG (CH) 1997-03-13 — — WO disclosed
US-5488160-A LEUKOTRIENE B4 RECEPTOR ANTAGONIST AS ANTIINFLAMMATORY AGENTS CIBA-GEIGY CORPORATION (US) 1996-01-30 — — US disclosed
US-5451700-A Leukotriene inhibitors CIBA-GEIGY CORPORATION (US) 1995-09-19 — — US disclosed
EP-0080053-B1 3,5-DIPHENYL-1H-1,2,4-TRIAZOLES WITH CONTRAGESTATIONAL ACTIVITY, PHARMACEUTICAL COMPOSITIONS THEREOF AND PROCESS FOR THEIR PREPARATION GRUPPO LEPETIT S.P.A. (IT) 1986-03-05 — — EP disclosed
US-4535090-A ANTIFERTILITY AGENTS; ABORTION GRUPPO LEPETIT S.P.A. (IT) 1985-08-13 — — US disclosed
EP-0080053-A1 3,5-Diphenyl-1H-1,2,4-triazoles with contragestational activity, pharmaceutical compositions thereof and process for their preparation GRUPPO LEPETIT S.P.A. (IT) 1983-06-01 — — EP disclosed
US-4127666-A ANTIEMETIC UNIVERSITE D'ORLEANS (FR) 1978-11-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050080121-A1 Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis PRCP, RNPEP, SARNP PPARG 2682/4885TDP1 1347/4885SLC6A2 4842/4885
US-20070281954-A1 Cyclohexyl-1,4-diamine compounds DPYD, PKD1, AOC1 PPARG 3713/4885TDP1 973/4885SLC6A2 923/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.